1. People's Republic of China Stocks

  2. •

    Consumer Defensive

  3. •

    Packaged Foods
CSPC Innovation Pharmaceutical Co., Ltd.

CSPC Innovation Pharmaceutical Co., Ltd.

300765.SZ
CSPC Innovation Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
36.20
CNY
+2.35
- -
50.85BMarket Cap
CSPC Innovation Pharmaceutical Co., Ltd.
300765.SZ
(Shenzhen Stock Exchange)

Recent

price

36.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
1.01
1.17
1.4
1.14
1.12
1.38
1.96
1.82
1.42
1.55
1.47
Revenue per Share
- -
- -
0.23
0.22
0.25
0.25
0.25
0.29
0.54
0.31
0.04
-0.17
-0.06
Basic EPS, GAAP
- -
- -
-0.01
-0.05
0.11
0.19
0.2
0.07
0.39
0.1
-1.22
-0.55
-0.28
Free Cash Flow per Basic Share
- -
- -
0.06
0.03
- -
- -
0.02
0.03
0.06
0.07
0.27
0.03
- -
Dividend per Share
- -
- -
0.57
0.77
1.01
1.08
1.41
1.44
1.93
2.06
1.95
1.75
1.92
Book Value per Share
- -
- -
0.57
0.8
1.06
2.13
2.23
2.43
2.91
3.76
3.05
1.85
2.9
Tangible Book Value per Share
- -
- -
883
884
886
1,105
1,180
1,337
1,337
1,397
1,399
1,393
1,401
Basic Weighted Avg Shares
651
742
890
1,031
1,240
1,257
1,317
1,850
2,626
2,539
1,981
2,158
2,058
Sales/Revenue/Turnover
19.41
17.75
24.63
24.1
22.21
24.23
26.02
24.82
28.92
6.88
-13.17
-24.89
-23.02
Operating Margin (%)
21
25
27
35
43
47
53
69
73
156
217
223
- -
Depreciation Expense
108
116
207
195
224
273
300
393
726
434
54
-241
-86
Net Income, GAAP
14.83
15.64
16.85
18.39
19.22
18.39
17.94
17.84
14.65
52.06
- -
- -
- -
Effective Tax Rate (%)
16.63
15.58
23.2
18.9
18.05
21.74
22.76
21.26
27.65
17.11
2.71
-11.18
-4.18
Profit Margin (%)
240
389
33
192
312
1,536
1,678
2,079
2,608
2,714
1,368
144
1,135
Working Capital
- -
120
- -
50
- -
- -
1
- -
20
1
- -
2
- -
LT Debt
537
627
572
767
999
2,415
2,687
3,298
3,944
5,483
4,496
2,795
4,292
Total Equity
- -
17.18
25.03
25.78
22.78
14.16
11
12.58
17.81
1.77
- -
- -
- -
Return on Invested Capital (%)
- -
25.79
36.3
28.26
25.85
25.2
20.83
21.84
32.03
26.16
- -
- -
- -
Return on Capital (%)
- -
30.89
45.28
32.97
28.43
26.17
20.96
21.93
32.31
15.94
1.92
-9.32
-3.12
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,405
1,405
1,405
Market Capitalization
31,098
52,360
72,424

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,802
2,849
2,880
Cash, Cash Equivalents & STI
1,342
1,299
1,281
Accounts Receivable, Net
314
398
474
Inventories
399
417
434
Total Current Liabilities
1,434
1,606
1,745
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.41%
5.1%
-37.83%
Free Cash Flow
-111.51%
-213.64%
-55.39%
Net Income, GAAP
-44.11%
-112.15%
-548.8%
Sales/Revenue/Turnover
12.82%
13.2%
8.93%
Total Cash Common Dividend
486.81%
71.35%
-90.26%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
524
448
507
502
1,981
2025
472
578
565
- -
2,158
2026
665
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
- -
- -
- -
0.04
2025
-0.02
- -
- -
- -
-0.17
2026
-0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.27
2025
- -
- -
- -
- -
0.03
2026
- -
- -
- -
- -
- -
Similar Companies
JBS S.A. (JBSS3.SA)
Emmi AG (0QM5.L)
WK Kellogg Co (KLG)
San Miguel Food and Beverage, Inc. (SMPFF)
MEGMILK SNOW BRAND Co.,Ltd. (2270.T)
Thai Vegetable Oil Public Company Limited (TVO-R.BK)
Business
CSPC Innovation Pharmaceutical Co., Ltd. operates as a wholly-owned subsidiary of CSPC Pharmaceutical Group, focusing on the production and sale of functional food ingredients and innovative pharmaceutical products. The company specializes in manufacturing two core product lines: chemically synthesized caffeine used as a food additive and vitamin C lozenges, offering a comprehensive product structure to meet diverse consumer needs within China’s functional food industry. CSPC Innovation has developed a significant brand advantage and product depth, positioning itself as a major global production base for synthetic caffeine. Founded in 1997 and headquartered in Shijiazhuang, China, the company leverages extensive research and development capabilities as part of the broader CSPC Group's pharmaceutical operations. Recent major developments include its transition towards becoming a core innovative drug platform within CSPC Group through strategic acquisitions and expansions. Notably, in 2025, CSPC Innovation undertook the acquisition of an additional 29% stake in Jushi Biologics for RMB 1.1 billion, increasing ownership to 80%, thereby strengthening its pipeline focused on antibody-drug conjugates, monoclonal antibodies, and mRNA vaccines. Jushi Biologics launched lead products such as enlonstobart and omalizumab in 2024, enhancing the group’s biologics offerings and innovation profile. The company also participates actively in licensing deals and fundraising efforts to support product development and expansion, aligning with CSPC Group’s broader strategic push into innovative drug development and global market growth. The company operates within the pharmaceutical and functional food industry sectors, targeting both domestic Chinese markets and over 100 countries internationally through export sales. Its operations are supported by CSPC's extensive R&D network, including centers in China, the United States, and other strategic locations. CSPC Innovation's growth strategy encompasses deepening its product portfolio in functional food additives while expanding into high-technology pharmaceuticals through research collaborations, acquisitions, and increased clinical trial activity. This strategy reflects a clear shift aiming to enhance its presence in both nutritional and therapeutic product markets, underpinned by robust innovation and internationalization efforts.